SAN FRANCISCO -- A new type of COVID-19 therapy is showing promise as a new tool to hijack the virus and slow down variants. It's a new weapon that could be added to the arsenal against COVID-19.

The common cold is typically caused by viruses, most often rhinoviruses, which infect the upper respiratory tract (nose and throat). 1 Zinc has been reported to block the replication of rhinovirus. By ...

Low vaccination rates for influenza viruses and the lack of an HSV vaccine underscore the need for a new approach to reduce viral transmission. Researchers have now used a clinical-grade antiviral ...

WEST LAFAYETTE, Ind. — Eradivir, a preclinical biotech company, has developed a patent-pending antiviral therapeutic that reduces lung viral loads of advanced-stage influenza in preclinical studies ...